您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Selonsertib(GS-4997)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Selonsertib(GS-4997)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Selonsertib(GS-4997)图片
CAS NO:1448428-04-3
包装与价格:
包装价格(元)
5mg电议
25mg电议
100mg电议
500mg电议
1g电议

产品介绍
Selonsertib (GS-4997) (GS-4997) 是一种口服生物可利用的选择性凋亡信号调节激酶 1 (ASK1) 抑制剂,pIC50 为 8.3,已被评估为糖尿病肾病和肾纤维化的实验性治疗药物。
Cas No.1448428-04-3
别名GS-4997
化学名5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide
Canonical SMILESO=C(NC1=NC(C2=NN=CN2C(C)C)=CC=C1)C3=CC(N4C=C(C5CC5)N=C4)=C(C)C=C3F
分子式C24H24FN7O
分子量445.49
溶解度≥ 44.5 mg/mL in DMSO, ≥ 88.8 mg/mL in EtOH
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Selonsertib (GS-4997) is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor.

ASK1, a redox-sensitive mitogen-activated protein kinase kinase kinase, functions as a key signaling node by promoting deleterious effects. ASK1 activation can cause downstream activation of the terminal MAPK kinases p38 and c-Jun N-terminal kinase, which stimulate production of inflammatory cytokines, induce fibrosis, promote apoptotic and necrotic cell death, increase aberrant cell proliferation, as well as contribute to metabolic perturbations.

In vitro: GS-4997 has been identified as a highly selective and potent ASK1 inhibitor that competed with ATP in the ASK1 catalytic kinase domain. Moreover, the ASK1 inhibition caused by GS-4997 was found to be significantly different in mechanism from bardoxolone methyl. GS- 4997 could also shut down cell signaling involved in pathogenesis, while bardoxolone methyl activated mRNA transcription in every cell exposed to drug. In addition, GS-4997 could selectively target affected cells in which the oxidative burden was high [1].

In vivo: So far, there is no animal in vivo data released.

Clinical trial: The phase II study regarding delineating study population, efficacy outcomes, treatment period as well as statistical methods to resolve specific challenges for DKD study has been designed based on the biology of oxidative stress signaling through ASK1, the biology of DKD pathogenesis, and solid statistical methods [1].

Reference:
[1] Lin JH et al.  Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33.